首页> 外文期刊>Molecular oncology. >Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor–normal samples in lung adenocarcinoma
【24h】

Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor–normal samples in lung adenocarcinoma

机译:通过整合miRNA和mRNA测序鉴定匹配的肿瘤正常样品在肺腺癌中的抑癌miRNA

获取原文
           

摘要

The roles of miRNAs in lung cancer have not yet been explored systematically at the genome scale despite their important regulatory functions. Here, we report an integrative analysis of miRNA and mRNA sequencing data for matched tumor–normal samples from 109 Korean female patients with non‐small‐cell lung adenocarcinoma (LUAD). We produced miRNA sequencing (miRNA‐Seq) and RNA‐Seq data for 48 patients and RNA‐Seq data for 61 additional patients. Subsequent differential expression analysis with stringent criteria yielded 44 miRNAs and 2322 genes. Integrative gene set analysis of the differentially expressed miRNAs and genes using miRNA–target information revealed several regulatory processes related to the cell cycle that were targeted by tumor suppressor miRNAs (TSmiR). We performed colony formation assays in A549 and NCI‐H460 cell lines to test the tumor‐suppressive activity of downregulated miRNAs in cancer and identified 7 novel TSmiRs (miR‐144‐5p, miR‐218‐1‐3p, miR‐223‐3p, miR‐27a‐5p, miR‐30a‐3p, miR‐30c‐2‐3p, miR‐338‐5p). Two miRNAs, miR‐30a‐3p and miR‐30c‐2‐3p, showed differential survival characteristics in the Tumor Cancer Genome Atlas (TCGA) LUAD patient cohort indicating their prognostic value. Finally, we identified a network cluster of miRNAs and target genes that could be responsible for cell cycle regulation. Our study not only provides a dataset of miRNA as well as mRNA sequencing from the matched tumor–normal samples, but also reports several novel TSmiRs that could potentially be developed into prognostic biomarkers or therapeutic RNA drugs.
机译:尽管miRNA具有重要的调节功能,但在基因组规模上尚未系统地研究miRNA在肺癌中的作用。在这里,我们报告了来自109名韩国非小细胞肺腺癌(LUAD)女性患者的匹配肿瘤正常样品的miRNA和mRNA测序数据的综合分析。我们提供了48位患者的miRNA测序(miRNA-Seq)和RNA-Seq数据以及另外61位患者的RNA-Seq数据。随后用严格的标准进行差异表达分析,得到44个miRNA和2322个基因。使用miRNA-靶标信息对差异表达的miRNA和基因进行的综合基因组分析揭示了与肿瘤抑制miRNA(TSmiR)靶向的细胞周期相关的几种调控过程。我们在A549和NCI-H460细胞系中进行了集落形成分析,以测试下调的miRNA在癌症中的肿瘤抑制活性,并鉴定了7种新颖的TSmiR(miR-144-5p,miR-218-1-3p,miR-223-3p ,miR‐27a‐5p,miR‐30a‐3p,miR‐30c‐2‐3p,miR‐338‐5p)。两种miRNA,miR-30a-3p和miR-30c-2-3p在肿瘤基因组图谱(TCGA)LUAD患者队列中显示出不同的生存特征,表明它们的预后价值。最后,我们确定了可能负责细胞周期调控的miRNA和靶基因的网络簇。我们的研究不仅提供了来自匹配的肿瘤正常样品的miRNA数据集,还提供了mRNA测序,而且还报告了几种可能被发展为预后生物标志物或治疗性RNA药物的新型TSmiR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号